Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Doss

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Journal of Medicinal Chemistry|November 12, 1993
Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylatesW T Ashton, S M Hutchins, W J Greenlee, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Dipeptidyl peptidase IV inhibitors derived from beta-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazoleWallace T Ashton, Rosemary M Sisco, Hong Dong, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 9, 2010
In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeysV B G Reddy, G A Doss, B V Karanam, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 22, 2001
Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humansG K Poon, Q Chen, Y Teffera, et al.
Journal of Medicinal Chemistry|March 13, 2008
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonistLinus S Lin, Sookhee Ha, Richard G Ball, et al.
Chemical Research in Toxicology|July 18, 2002
Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formationQing Chen, Jason S Ngui, George A Doss, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 4, 2025
Characterizing Elephant MDM2's Role in p53 RegulationEmma Palefsky, Himani K Patel, Trey A Doss, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 28, 2005
Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in ratsQing Chen, George A Doss, Elaine C Tung, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 18, 2002
Metabolism of a thiazole benzenesulfonamide derivative, a potent and elective agonist of the human beta3-adrenergic receptor, in rats: identification of a novel isethionic acid conjugateWei Tang, Ralph A Stearns, Randall R Miller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 23, 2002
The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjectsRita A Halpin, Arturo G Porras, Leslie A Geer, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|November 12, 1993
Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylatesW T Ashton, S M Hutchins, W J Greenlee, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Dipeptidyl peptidase IV inhibitors derived from beta-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazoleWallace T Ashton, Rosemary M Sisco, Hong Dong, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 9, 2010
In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeysV B G Reddy, G A Doss, B V Karanam, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 22, 2001
Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humansG K Poon, Q Chen, Y Teffera, et al.
Journal of Medicinal Chemistry|March 13, 2008
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonistLinus S Lin, Sookhee Ha, Richard G Ball, et al.
Chemical Research in Toxicology|July 18, 2002
Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formationQing Chen, Jason S Ngui, George A Doss, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 4, 2025
Characterizing Elephant MDM2's Role in p53 RegulationEmma Palefsky, Himani K Patel, Trey A Doss, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 28, 2005
Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in ratsQing Chen, George A Doss, Elaine C Tung, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 18, 2002
Metabolism of a thiazole benzenesulfonamide derivative, a potent and elective agonist of the human beta3-adrenergic receptor, in rats: identification of a novel isethionic acid conjugateWei Tang, Ralph A Stearns, Randall R Miller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 23, 2002
The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjectsRita A Halpin, Arturo G Porras, Leslie A Geer, et al.
Pageof 13